Expertise in
24
conditions

Dr. David Greenstein

Dermatology
Office
138 Conant St Ste 1, 
Beverly, MA 
Expertise in
24
conditions
Office
138 Conant St Ste 1, 
Beverly, MA 

Overview

David Greenstein is a Dermatologist in Beverly, Massachusetts. Dr. Greenstein is highly rated in 24 conditions, according to our data. His top areas of expertise are Universal Acquired Melanosis, Liver Spots, Actinic Keratosis, and Plaque Psoriasis.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Dermatology

Licenses

Dermatology in MA

Hospital Affiliations

Northeast Hospital Corporation
Anna Jaques Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Nippon Life
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 26 Less Insurance Carriers -

Locations

Office
138 Conant St Ste 1, Beverly, MA 01915

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 26, 2024
Intervention Type: Drug, Biological
Study Drug: ASLAN004
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 28, 2023
Intervention Type: Drug
Study Drug: LY3041658
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials
Similar Doctors
Expertise in
37
conditions
Dr. Joseph Merola
Dermatology
Expertise in
37
conditions
Dr. Joseph Merola
Dermatology

Brigham And Women's Hospital

221 Longwood Ave, 
Boston, MA 
 (19.1 miles away)
617-732-4918
Languages Spoken:
English
See accepted insurances

Joseph Merola is a Dermatologist in Boston, Massachusetts. Dr. Merola is highly rated in 37 conditions, according to our data. His top areas of expertise are Psoriasis, Cutaneous Lupus Erythematosus (CLE), Psoriatic Arthritis, and Arthritis.

Arash Mostaghimi
Expertise in
32
conditions
Dr. Arash Mostaghimi
Dermatology
Expertise in
32
conditions
Dr. Arash Mostaghimi
Dermatology

Brigham Dermatology Associates

221 Longwood Avenue 1st Floor Brigham And Women's At 221 Longwood Boston, 1st Floor Brigham And Women's At 221 Longwood, 
Boston, MA 
 (19.2 miles away)
617-732-4918
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arash Mostaghimi is a Dermatologist in Boston, Massachusetts. Dr. Mostaghimi is highly rated in 32 conditions, according to our data. His top areas of expertise are Alopecia Areata, Autosomal Recessive Hypotrichosis, Pyoderma Gangrenosum, and Cellulitis.

Ruth A. Vleugels
Expertise in
27
conditions
Dr. Ruth A. Vleugels
Dermatology
Expertise in
27
conditions
Dr. Ruth A. Vleugels
Dermatology

Brigham Dermatology Associates

221 Longwood Avenue 1st Floor Brigham And Women's At 221 Longwood Boston, 1st Floor Brigham And Women's At 221 Longwood, 
Boston, MA 
 (19.2 miles away)
617-732-4918
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ruth Vleugels is a Dermatologist in Boston, Massachusetts. Dr. Vleugels is highly rated in 27 conditions, according to our data. Her top areas of expertise are Dermatomyositis, Eosinophilic Fasciitis, Cutaneous Lupus Erythematosus (CLE), and Discoid Lupus Erythematosus (DLE).

Frequently Asked Questions about Dr. David Greenstein

How do I make an appointment with Dr. David Greenstein?

You can book an appointment with Dr. David Greenstein by calling their office at 978-927-5254. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David Greenstein a top-rated expert for Universal Acquired Melanosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David Greenstein is classified as an Distinguished expert for Universal Acquired Melanosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David Greenstein specialize in?

While Dr. David Greenstein is a Dermatology, they have specific expertise in Universal Acquired Melanosis, Liver Spots, and Actinic Keratosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. David Greenstein accept my insurance?

Dr. David Greenstein accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 978-927-5254 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenstein's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile